Effects of terlipressin on water excretion after oral water load test in nonazotemic cirrhotic patients with ascites without hyponatremia

Scandinavian Journal of Gastroenterology

Volumn 45, Issue 12, 2010, Pages 1509-1515

  Kalambokis, Georgios N ^a   Pappas, Konstantinos ^a   Baltayiannis, Gerasimos ^a   Katsanou, Alexandra ^a   Tsianos, Epameinondas V ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Ascites; Cirrhosis; Terlipressin; Water load test

Indexed keywords

FUROSEMIDE; SODIUM; SPIRONOLACTONE; TERLIPRESSIN;

ADULT; ARTICLE; ASCITES; BOLUS INJECTION; CLINICAL ARTICLE; CREATININE CLEARANCE; DISEASE SEVERITY; DIURESIS; DIURETIC THERAPY; DRUG EFFECT; FEMALE; FLUID INTAKE; HEART OUTPUT MEASUREMENT; HUMAN; LIVER CIRRHOSIS; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; SODIUM EXCRETION; SODIUM URINE LEVEL; SYSTEMIC VASCULAR RESISTANCE; WATER LOADING;

ASCITES; DIURESIS; DRINKING; FEMALE; HUMANS; HYPONATREMIA; LIVER CIRRHOSIS; LYPRESSIN; MALE; MIDDLE AGED; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 78649281967     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2010.510576     Document Type: Article

References (30)

1. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7.
2. Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000;32(Suppl 1):157-70.
3. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003;38(Suppl): 69-89.
4. Gines P, Fernandez-Esparrach G, Arroyo V, Rodes J. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997;17:175-89.
5. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, Uriz J, Quinto L, Ventura PJ, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001;34:46-52.
6. Castellano G, Solis-Herruzo JA, Morillas JD, Larrodera L, Coca C, Gamarra-Gonzalez A, et al. Antidiuretic hormone and renal function after water loading in patients with cirrhosis of the liver. Scand J Gastroenterol 1991;26:49-57.
7. Gatta A, Caregaro L, Angeli P, Merkel C, Menon F, Rondana M, et al. Impaired renal water excretion in liver cirrhosis. The role of reduced distal delivery of sodium. Scand J Gastroenterol 1988;23:523-8.
8. Hendrickse MT, Triger DR. Vagal dysfunction and impaired urinary sodium and water excretion in cirrhosis. Am J Gastroenterol 1994;89:750-7.
9. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-36.
10. Cosby RL, Yee B, Schrier RW. New classification with prognostic value in cirrhotic patients. Miner Electrolyte Metab 1989;15:261-6.
11. Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 2006;43:385-94.
12. Kalambokis GN, Tsianos EV. Vasoconstrictor therapy for patients with cirrhosis with ascites but without hepatorenal syndrome. Hepatology 2008;48:686.
13. Krag A, Moller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007;46:1863-71.
14. Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsianos EV. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol 2007;46:213-21.
15. Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S, et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998;28:937-43.
16. Hirasawa A, Shibata K, Kotosai K, Tsujimoto G. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem Biophys Res Commun 1994;203:72-9.
17. Pugh R, Murry-Lyon I, Dawson J, Pietroni M, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
18. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003;38:258-66.
19. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-8.
20. Escorsell A, Bandi JC, Moitinho E, Feu F, Garcia-Pagan JC, Bosch J, et al. Time profile of the haemodynamic effects of terlipressin in portal hypertension. J Hepatol 1997;26:621-7.
21. Epstein M. Derangement of renal water handling in liver disease. Gastroenterology 1985;89:1415-25.
22. Bichet DG, Van Putten VJ, Schrier RW. Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N Engl J Med 1982;307:1552-7.
23. Bichet DG, Szatalowicz V, Chaimovitz C, Schrier RW. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 1982;96:413-7.
24. Castellano G, Solis-Heruzo JA, Gonzalez A, Morillas JD, Moreno D, Munoz T, et al. Plasma arginine vasopressin response to oral, gastric, and intravenous water load in patients with cirrhosis. Gastroenterology 1994;106:678-85.
25. Moller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995;109:1917-25.
26. Kalambokis G, Economou M, Kosta P, Papadimitriou K, Pappas C, Katsaraki A, et al. Effects of somatostatin, terlipressin and somatostatin plus terlipressin on portal and systemic hemodynamics and renal sodium excretion in patients with cirrhosis. J Gastroenterol Hepatol 2005;20:1075-81.
27. Narahara Y, Kazanawa H, Taki Y, Kimura Y, Atsukawa M, Katakura T, et al. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. J Gastroenterol Hepatol 2009;24:1791-7.
28. Krag A, Bendtsen F, Pedersen EB, Holstein-Rathlou NH, Moller S. Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects. Am J Physiol Renal Physiol 2008;295: FI295-300.
29. Treschan TA, Peters J. The vasopressin system: physiology and clinical strategies. Anesthesiology 2006;105:599-612.
30. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las HD, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of